Today: 21 May 2026

Philip Morris (PM) stock price slips today despite fresh target hikes as Zyn battle stays in view

Philip Morris (PM) stock price slips today despite fresh target hikes as Zyn battle stays in view

Philip Morris International shares fell 1.4% to $180.17 in Monday afternoon trading after a new debt shelf filing and recent earnings guidance. Investors focused on competition in nicotine pouches and upcoming U.S. economic data. The stock traded between $179.85 and $182.54, about 1.6% below its 52-week high. Several analysts raised their price targets following the company’s updated 2026 outlook.
9 February 2026
·
Arrowhead Pharmaceuticals stock swings as S&P MidCap 400 move lands and Goldman flags 2026 catalysts (ARWR)

Arrowhead Pharmaceuticals stock swings as S&P MidCap 400 move lands and Goldman flags 2026 catalysts (ARWR)

Arrowhead Pharmaceuticals shares fell 0.7% to $64.10 in afternoon trading Monday after moving from the S&P SmallCap 600 to the S&P MidCap 400. The stock saw heavy volume and a wide intraday range. Goldman Sachs maintained a Neutral rating and $85 target, citing key 2026 pipeline data and competition from Ionis Pharmaceuticals. Arrowhead recently reported Q1 revenue of $264 million and 22 cents EPS.
9 February 2026
··
Microchip stock drops on $600 million convertible-notes plan — what investors watch next

Microchip stock drops on $600 million convertible-notes plan — what investors watch next

Microchip Technology shares fell about 2% to $74.52 after the company announced a $600 million convertible notes offering. Proceeds will fund capped-call hedges and repay commercial paper borrowings. The notes mature in 2030 and will be sold privately to institutional buyers. Traders are watching for final pricing and hedging flows that could move the stock.
9 February 2026
··
Merck stock drops nearly 4%: why MRK is lagging the market today

Merck stock drops nearly 4%: why MRK is lagging the market today

Merck shares fell 3.9% to $117.16 Monday, underperforming the broader market as investors weighed patent risks and 2026 earnings guidance. Amgen, Pfizer, and AbbVie also declined. Merck last week projected 2026 sales of up to $67 billion and warned of a $2.5 billion hit from generic competition and weaker COVID-19 drug sales. The Dow lagged as Merck and Amgen dragged on the index.
9 February 2026
··
Intuit stock drops in afternoon trade as TD Cowen cuts target and AI jitters linger

Intuit stock drops in afternoon trade as TD Cowen cuts target and AI jitters linger

Intuit shares fell 1.3% to $438.01 Monday, underperforming a 2.4% gain in the broader software sector. TD Cowen cut its price target to $658, citing AI concerns, while Jefferies maintained an $850 target, calling AI fears “too harsh.” The stock traded between $431.53 and $447.00. Investors are watching for Intuit’s quarterly results on Feb. 26.
9 February 2026
··
Palo Alto Networks stock jumps as Nasdaq sets a close date for the CyberArk deal

Palo Alto Networks stock jumps as Nasdaq sets a close date for the CyberArk deal

Palo Alto Networks shares rose 3.4% to $164.81 Monday after Nasdaq set a tentative Feb. 11 closing date for its $25 billion CyberArk merger. CyberArk shares gained 4% to $407.38, with trading set to halt after-hours Feb. 10. The deal gives CyberArk holders $45 cash and 2.2005 Palo Alto shares per share. Investors await Palo Alto’s quarterly results on Feb. 17 for updates on integration and demand.
9 February 2026
····
Thermo Fisher (TMO) stock nudges higher after filing for new bond sale tied to Clario deal

Thermo Fisher (TMO) stock nudges higher after filing for new bond sale tied to Clario deal

Thermo Fisher shares rose 0.1% to $543.48 Monday after the company filed for a four-part senior notes offering to help fund its planned Clario acquisition. The preliminary prospectus left key terms blank and showed $39.38 billion in consolidated debt as of Dec. 31, 2025. S&P rated the proposed debt ‘A-’. Executive Gianluca Pettiti filed to sell 400 shares valued at $216,480.
9 February 2026
·
AST SpaceMobile stock (ASTS) whipsaws in New York trade as the next satellite milestone nears

AST SpaceMobile stock (ASTS) whipsaws in New York trade as the next satellite milestone nears

AST SpaceMobile shares fell 0.5% to $101.28 by 2:13 p.m. EST after swinging between $98.95 and $108.25 in volatile trading. The move came as broader U.S. markets rose and investors awaited updates on the BlueBird 7 satellite launch, now scheduled for no earlier than late February. Blue Origin will handle the launch from Cape Canaveral. The company still needs more regulatory approvals and capital for its planned 2026 rollout.
9 February 2026
·
Boeing stock ticks up after Air Force C-17 upgrade award, with BA in focus ahead of jobs, CPI

Boeing stock ticks up after Air Force C-17 upgrade award, with BA in focus ahead of jobs, CPI

Boeing shares rose 0.4% to $243.98 Monday after announcing a U.S. Air Force contract to modernize the C-17A flight deck. Curtiss-Wright said Boeing picked it to supply mission computers for the upgrade, valuing its contract at over $400 million. The Pentagon listed Boeing’s deal at $266.6 million, with work through 2031. Traders are watching U.S. jobs and inflation data later this week.
9 February 2026
·
Why Constellation Energy (CEG) stock is up today: new 380‑MW Texas data center deal

Why Constellation Energy (CEG) stock is up today: new 380‑MW Texas data center deal

Constellation Energy shares rose 3.6% to $270.81 after its Calpine unit signed a 380-MW power deal with CyrusOne for a new Texas data center. The agreement lifts CyrusOne’s contracted power in Texas above 1,100 MW. Constellation also announced a 20-year energy contract for the Tennessee Titans’ new stadium. Vistra, NRG, and Talen Energy shares also gained.
9 February 2026
··
P&G stock slides while Wall Street rises — what investors are watching this week

P&G stock slides while Wall Street rises — what investors are watching this week

Procter & Gamble shares fell 1.2% to $157.24 in Monday afternoon trading, underperforming the broader market as consumer-staples stocks weakened. Investors are awaiting U.S. jobs and inflation data due later this week. P&G’s last update showed flat sales and profit, with volume declines in key segments. The company declared a quarterly dividend of $1.0568 per share, payable Feb. 17.
9 February 2026
···
Super Micro stock slips again: what SMCI investors are watching after the margin squeeze

Super Micro stock slips again: what SMCI investors are watching after the margin squeeze

Super Micro Computer shares fell 2% to around $33.68 Monday after reporting gross margin dropped to 6.3% from 11.8% a year earlier, citing $142 million in tariff costs and higher inventory write-downs. The company disclosed “material weaknesses” in internal controls and is working on fixes. Revenue outlook remains bullish, but investors are watching for margin recovery and updates at the April 15 shareholder meeting.
9 February 2026
··
Home Depot stock slips as Wall Street pushes higher; what to watch before HD earnings

Home Depot stock slips as Wall Street pushes higher; what to watch before HD earnings

Home Depot shares fell 1.3% to $380.30 Monday afternoon, underperforming a rising U.S. market. Investors are awaiting key U.S. jobs and inflation data this week, followed by Home Depot’s quarterly earnings on Feb. 24. Lowe’s also slipped, while major indexes gained. Home Depot previously warned that comparable sales may be flat to up 2% for fiscal 2026.
9 February 2026
···
1 … 297 298 299 300 301 … 1,961

Stock Market Today

  • Bitmine Immersion Technologies Uplists to NYSE, Holds 5M+ ETH as Ethereum Proxy, Launches MAVAN Staking
    May 21, 2026, 12:11 AM EDT. Bitmine Immersion Technologies (NYSE:BMNR) has become a major Ethereum proxy by accumulating over 5 million ETH, representing more than 4.3% of Ethereum's total supply. The company uplisted to the NYSE and introduced MAVAN, an institutional-grade Ethereum staking platform, shifting its focus beyond mining to include staking services. BMNR stock closed at $19.39, trading below analyst targets and experiencing recent price declines despite longer-term gains. Investors should watch Ethereum price trends, staking yields, and institutional adoption of MAVAN, while noting BMNR remains loss-making and has diluted shareholders.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop